首页> 外文期刊>Urology >Microdissection testicular sperm extraction and salvage hormonal treatment in patients with postchemotherapy azoospermia
【24h】

Microdissection testicular sperm extraction and salvage hormonal treatment in patients with postchemotherapy azoospermia

机译:化疗后无精症患者睾丸显微解剖精子的提取与激素治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Objective To investigate the efficacy of microdissection testicular sperm extraction (micro-TESE) in patients with postchemotherapy azoospermia (PCA), we reviewed our results of micro-TESE combined with intracytoplasmic sperm injection, which are the most commonly used fertility treatments. Furthermore, we investigated the efficacy of hormonal therapy for men who failed to recover sperm after micro-TESE. Methods Twenty-six patients with PCA with the mean age of 34.6 years (range, 23-42) were included in this study. The cancer types included testicular cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, neuroblastoma, osteosarcoma, and malignant pheochromocytoma. The mean interval from chemotherapy to micro-TESE was 14.8 years (range, 7-25), and the mean age of the female partners was 34.1 years. Results Sperm were retrieved in 11 (42%) of the patients. Six patients who did not obtain successful sperm retrieval underwent human chorionic gonadotropin-based hormonal therapy, and sperm were retrieved from 2 patients by a second micro-TESE. In total, 7 (27%) pregnancies and 5 (19%) live birth deliveries were achieved. Patients with PCA after testicular cancer treatment were able to achieve a high rate (75%) of sperm retrieval and that exposure to alkylating agents resulted in lower sperm retrieval rates. Conclusion Micro-TESE-intracytoplasmic sperm injection is an effective fertility treatment for patients with PCA. Furthermore, patients who could not achieve successful sperm retrieval by micro-TESE might obtain improved outcomes with hormonal therapy, indicating that these treatments might provide the patients with PCA with the opportunity to retrieve sperm and father a child.
机译:目的探讨显微解剖睾丸精子提取术(micro-TESE)对化疗后无精子症(PCA)患者的疗效,我们综述了微型TESE联合胞浆内精子注射的结果,这是最常用的生育治疗方法。此外,我们研究了激素疗法对微型TESE后未能恢复精子的男性的疗效。方法纳入平均年龄34.6岁(范围23-42岁)的26例PCA患者。癌症类型包括睾丸癌,霍奇金淋巴瘤,非霍奇金淋巴瘤,白血病,神经母细胞瘤,骨肉瘤和恶性嗜铬细胞瘤。从化疗到micro-TESE的平均间隔为14.8年(范围7-25),女性伴侣的平均年龄为34.1岁。结果11名(42%)患者精子被检出。六名未能成功获得精子的患者接受了基于绒毛膜促性腺激素的激素治疗,第二次微型TESE从两名患者中提取了精子。总共有7例(27%)怀孕和5例(19%)活产。睾丸癌治疗后的PCA患者能够获得较高的精子回收率(75%),而暴露于烷基化剂会导致较低的精子回收率。结论Micro-TESE胞浆内精子注射是治疗PCA的有效方法。此外,无法通过micro-TESE成功获得精子的患者可以通过激素疗法获得更好的结果,这表明这些疗法可能为PCA患者提供了获得精子并育儿的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号